Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.57 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.57 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.52 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.52 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.52 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.52 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.52 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7165877 | 0.90 | CXCR2 (0.55) | CXCR2CXCR1KCNMA1MAPTMEN1 | |
| SCHEMBL7165961 | 0.86 | CXCL8 (0.64) | ALDH1A1GAAMAPTMEN1KMT2A | |
| SCHEMBL7161755 | 0.83 | MEN1 (0.58) | KCNMA1ALDH1A1GAAMAPTHPGD | |
| SCHEMBL7165547 | 0.81 | L3MBTL1 (0.57) | CXCR2CXCR1ALDH1A1MAPTHPGD | |
| SCHEMBL7164914 | 0.81 | GAA (0.64) | KCNMA1ALDH1A1GAAMAPTMEN1 | |
| SCHEMBL7169174 | 0.81 | ALDH1A1 (0.56) | CXCR1ALDH1A1GAAMAPTMEN1 | |
| SCHEMBL7166087 | 0.80 | CXCL8 (0.51) | CXCR1ALDH1A1MAPTCXCL8CYP1A2 | |
| SCHEMBL7165423 | 0.79 | CXCL8 (0.68) | CXCR2CXCR1CXCL8CYP2C9CAMK2A | |
| SCHEMBL7161781 | 0.79 | CXCL8 (0.77) | CXCR2CXCR1KCNMA1GAAMEN1 | |
| SCHEMBL7164948 | 0.78 | CXCL8 (0.59) | CXCR1ALDH1A1GAAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552077-B2 | Kidney disorders | EXOCELL, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1242069-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6355680-B1 | BLOCKING REACTION OF GLUCOSE AND ALBUMIN | EXOCELL, INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | EXOCELL, INC. | 2001-10-25 | — | — | US | disclosed |
| WO-2001003684-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | ALB, AGER, TTR | CXCR2 4689/4885CXCR1 4283/4885KCNMA1 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.